• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NATEGLINIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • NATEGLINIDE chembl:CHEMBL783 Approved

    Alternate Names:

    A-4166
    DJN-608
    SDZ DJN 608
    AY-4166
    STARSIS
    STARLIX
    SDZ-DJN-608
    NATEGLINIDE
    (-)-N-(TRANS-4-ISOPROPYLCYCLOHEXANECARBONYL)-D-PHENYLALANINE
    AY 4166
    A 4166
    AY4166
    DJN608
    STARLIX®
    TRANS-N-{[4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL}-D-PHENYLALANINE
    chembl:CHEMBL783
    drugbank:00731
    pubchem.compound:60026
    chemidplus:105816-04-4
    rxcui:274332

    Drug Info:

    Year of Approval 2000
    Drug Class hypoglycemic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidiabetic
    (3 More Sources)

    Publications:

    Kalliokoski A et al., 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide., J Clin Pharmacol
    Hu et al., 2000, Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide., J. Pharmacol. Exp. Ther.
    Chachin et al., 2003, Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels., J. Pharmacol. Exp. Ther.
    Hansen et al., 2002, Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1., Diabetes
    Sunaga et al., 2001, The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide., Eur. J. Pharmacol.
    Norman et al., 2001, Nateglinide: A structurally novel, short-acting, hypoglycemic agent., Drugs Today
    Dornhorst, 2001, Insulinotropic meglitinide analogues., Lancet
    Cheng Y et al., 2013, Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers., Eur J Clin Pharmacol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
  • NATEGLINIDE   ABCC8

    Interaction Score: 2.91

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker
    Trial Name Starlix

    PMIDs:
    10773014 12604678 12196472 11716850 12764427 11728565


    Sources:
    TdgClinicalTrial ChemblInteractions

  • NATEGLINIDE   KCNJ1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • NATEGLINIDE   KCNJ11

    Interaction Score: 0.44

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TEND

  • NATEGLINIDE   CALCA

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NATEGLINIDE   SLCO1B1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18187595


    Sources:
    PharmGKB

  • NATEGLINIDE   CYP2C9

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22842957 22931300


    Sources:
    DTC PharmGKB

  • NATEGLINIDE   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NATEGLINIDE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NATEGLINIDE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NATEGLINIDE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • TdgClinicalTrial: NATEGLINIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: NATEGLINIDE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class hypoglycemic agents
    Year of Approval 2000

    Publications:

  • DTC: NATEGLINIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL783 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: nateglinide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cheng Y et al., 2013, Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers., Eur J Clin Pharmacol
    Kalliokoski A et al., 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide., J Clin Pharmacol

  • TTD: Nateglinide

    • Version: 2020.06.01

    Alternate Names:
    D06PSS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL783

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL783

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21